Cargando…

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

INTRODUCTION: Infiltration of breast tumors by tumor-infiltrating lymphocytes (TIL) has been associated with sensitivity to anthracycline-based chemotherapy. However, it is unclear whether this is true within the estrogen receptor-alpha (ER)-negative subset of breast tumors that frequently manifest...

Descripción completa

Detalles Bibliográficos
Autores principales:	West, Nathan R, Milne, Katy, Truong, Pauline T, Macpherson, Nicol, Nelson, Brad H, Watson, Peter H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326568/ https://www.ncbi.nlm.nih.gov/pubmed/22151962 http://dx.doi.org/10.1186/bcr3072

Ejemplares similares

Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Webb, John R, et al.
Publicado: (2014)

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
por: West, N R, et al.
Publicado: (2013)

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
por: Milne, Katy, et al.
Publicado: (2012)

Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer
por: Bacinschi, Xenia Elena, et al.
Publicado: (2020)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2009)

Correction: Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2013)

Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
por: Honda, Chikako, et al.
Publicado: (2021)

Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)
por: West, Nathan R., et al.
Publicado: (2011)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
por: Long, Treya M., et al.
Publicado: (2019)

Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy
por: Tzolos, E., et al.
Publicado: (2020)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
por: Yndestad, Synnøve, et al.
Publicado: (2017)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
por: Mullan, Paul B., et al.
Publicado: (2019)

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
por: Nederlof, I., et al.
Publicado: (2022)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
por: Xia, Peng, et al.
Publicado: (2023)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
por: Blaes, Anne H, et al.
Publicado: (2015)

PD-L1 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2017)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells
por: Chewchuk, Simon, et al.
Publicado: (2017)

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer
por: Miyoshi, Yuichiro, et al.
Publicado: (2019)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
por: Absmaier, Magdalena, et al.
Publicado: (2018)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers
por: Fukui, Reiko, et al.
Publicado: (2023)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Long QT syndrome and torsade de pointes after anthracycline chemotherapy
por: Colombo, N, et al.
Publicado: (2009)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain
por: Costello, Benedict T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r7laqpmo9ii4e7179rpiu4gj2p